Brief: Ac Immune Partner Life Molecular Imaging Initiates Phase 3 Study For Alzheimer’S Disease Drug
18/01/2023 13:50
Jan 18 (Reuters) - AC Immune SA ACIU.O :
* AC IMMUNE PARTNER LIFE MOLECULAR IMAGING INITIATES PHASE 3
STUDY
OF TAU PET DIAGNOSTIC PI-2620 FOR ALZHEIMER’S DISEASE
* AC IMMUNE SA - FIRST ALZHEIMER'S PATIENT IMAGED WITH
PI-2620 IN
ADVANCE, PIVOTAL PHASE 3 TRIAL
Source text for Eikon: ID:nGNX8QvQ3p
Further company coverage: ACIU.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AC Immune AG
See all newsAC Immune rises after Parkinson's drug shows promise in mid-stage trial
Brief: Ac Immune Reports Positive Safety & Immunogenicity At Week-100 In Part 1 Of Vacsyn Phase 2 Trial Of Aci-7104
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,
U.S. STOCKS ON THE MOVE-Duke Energy, Sea, Cardinal Health